Polatuzumab vedotin
Based on 1 publication(s) in Google Scholar
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
For research use only. We do not sell to patients.
- Purity: 99.29%
- CAS No.: 1313206-42-6
- Molecular Weight:150000 (average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-152963
Tisotumab vedotin
-
HY-P99107A
Brentuximab vedotin (solution)
-
HY-P99349
Loncastuximab tesirine
-
HY-138298A
Trastuzumab deruxtecan
-
HY-141601
Telisotuzumab vedotin
-
HY-P9921
Trastuzumab emtansine
-
HY-P9985
Disitamab vedotin
-
HY-141598
Datopotamab deruxtecan (solution)
-
HY-132254A
Sacituzumab govitecan (solution)
-
HY-132258A
Mirvetuximab soravtansine (solution)
-
HY-P99813
Patritumab deruxtecan
-
HY-P3239
Belantamab mafodotin
Publications Citing Use of MedChemExpress (MCE) Polatuzumab vedotin
More
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)[2]
-
Dosage:0.3, 1, 3, 6, 12 mg/kg
-
Administration:I.v.; once
-
Result:Showed dose-dependent tumour growth inhibition.
Chemical Information
-
CAS No. 1313206-42-6
-
Appearance Solid
-
Molecular Weight 150000 (average)
-
Color White to off-white
-
SMILES
[Polatuzumab vedotin]
-
Preparation Instructions
The product can be reconstituted/diluted with sterile PBS or saline.
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
Direct Visualization and Quantitative Modeling of Mass Transport Limitation in Biomolecular Kinetics via Imaging-Based Meta-SPR. [Abstract]2026 Mar 24;98(11):8382-8393. PMID: 41814478
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716. [Content Brief]
[2]. Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Polatuzumab vedotin Related Classifications
HY-132253 Related Classifications
Powered by Bioz